177785-47-6 Usage
Description
(2S,3S)-3-METHYL-2-(3-OXO-2,3-DIHYDRO-1,2-BENZISOTHIAZOL-2-YL)VALERIC ACID, also known as Riluzole, is a pharmaceutical compound with a unique chemical structure that features a valeric acid side chain and a benzisothiazolone ring. This structure contributes to its pharmacological activity, making it a medication used to treat specific neurological conditions. Riluzole works by decreasing the release of glutamate in the brain, which is believed to slow down the progression of certain diseases. It also has neuroprotective properties, which may offer additional benefits in the treatment of neurodegenerative disorders.
Uses
Used in Pharmaceutical Industry:
Riluzole is used as a therapeutic agent for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. By reducing the release of glutamate, Riluzole helps to slow down the progression of ALS, providing relief and improving the quality of life for patients.
Additionally, Riluzole is used as a treatment for a type of anxiety disorder. Its neuroprotective properties are believed to contribute to its effectiveness in managing anxiety symptoms.
Riluzole is also being investigated for its potential use in other neurodegenerative diseases due to its neuroprotective properties, which may offer further benefits in these conditions.
Used in Research and Development:
In the field of medical research, Riluzole serves as a valuable compound for studying the mechanisms of neurodegenerative diseases and the role of glutamate in the brain. Its use in research can lead to a better understanding of these conditions and the development of new therapeutic strategies.
Formulation and Administration:
Riluzole is available in tablet form and is typically taken orally. It is generally well-tolerated, but may cause side effects such as dizziness, nausea, and liver problems. As with any medication, it is essential to follow the prescribed dosage and consult with a healthcare professional for proper administration and monitoring.
Check Digit Verification of cas no
The CAS Registry Mumber 177785-47-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,7,8 and 5 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 177785-47:
(8*1)+(7*7)+(6*7)+(5*7)+(4*8)+(3*5)+(2*4)+(1*7)=196
196 % 10 = 6
So 177785-47-6 is a valid CAS Registry Number.
177785-47-6Relevant articles and documents
Development and pilot-scale demonstration of a process for inhibitors of the HIV nucleocapsid protein, NCp7
Fiore, Phillip J.,Puls, Timothy P.,Walker, Jonathan C.
, p. 151 - 156 (1998)
A manufacturing process to prepare two antiretroviral agents that denature the HIV-1 nucleocapsid protein (NCp7) has been developed and demonstrated on a pilot scale. 2,2′-Dithiobis-(benzoyl chloride) (4), prepared from commercially available 2,2′-dithiobis(benzoic acid) (3), was coupled directly with L-isoleucine to give the potential anti-HIV compound [S-(R*,R*)]-2-{[2-[[2-[(1-carboxy-2-methylbutyl)carbamoyl]phenyl] dithio]-benzoyl]amino}-3-methylpentanoic acid (2) thereby eliminating the α-amino acid protection and deprotection steps used in the original synthesis. Compound 2 was oxidized by bromine to a second potential anti-HIV compound [S-(R*,R*)]-3-methyl-2-(3-oxo-3H-benzo[d]isothiazol-2-yl)pentanoic acid (1). The intermediacy of the hydrobromide salt of 1 provided an effective purity control in the production of the pharmaceutical agent. Cost, operational, safety, environmental, and equipment considerations were taken into account during the course of development.
Biophysical characterization of zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2'-dithiobis[benzamides] and benzisothiazolones
Loo, Joseph A.,Holler, Tod P.,Sanchez, Joseph,Gogliotti, Rocco,Maloney, Lisa,Reily, Michael D.
, p. 4313 - 4320 (2007/10/03)
HIV nucleocapsid protein (NCp7) has been suggested as a possible target for 2,2'-dithiobis[benzamide] and benzisothiazolone agents that inhibit viral replication in infected cells (Rice et al. Science 1995, 270, 1194-1197). The solution behavior of these
